 Pfenex Inc. NYSE American: PFNX is a development and licensing biotechnology company focused on leveraging its proprietary protein production platform, Pfenex Expression Technology, to develop next generation and novel protein therapeutics to meaningfully improve existing therapies and create novel therapies for some of the biological targets linked to critical diseases still waiting to successfully be addressed. Pfenex has developed a pipeline that is diversified across multiple assets, including a U.S. Food and Drug Administration FDA-approved PF708 product indicated for the treatment of osteoporosis in certain patients at high risk for fracture, and novel and next generation therapeutic product candidates. We believe this is an exciting time for Pfenex as we continue to work toward opportunities and potential milestones for our three lead programs: PF708, including the FDA-approved PF708 product, our collaboration with Jazz Pharmaceuticals to develop PF743 JZP-458 and PF745 JZP-341, as well as our CRM197 based collaborations, stated Eef Schimmelpennink, Chief Executive Officer of Pfenex. 